Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2693 phase 2b trial in PNPLA3-risk-allele non-cirrhotic NASH with fibrosis
2022-001629-65Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Jan 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and Nonalcoholic steatohepatitis (NASH) comparing AZD2693 with Placebo (2 arms). Primary endpoint: Resolution of NASH with no worsening of fibrosis after Week 52. Started Jan 2023; status: active.
02
Drugs
AZD2693
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on 2022-001629-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001629-65.